Benjamin Edwards’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.05M Buy
87,085
+6,204
+8% +$77.6K 0.01% 792
2026
Q2
$1.37M Sell
80,881
-1,682
-2% -$23.5K 0.01% 698
2026
Q1
$1.06M Buy
82,563
+3,363
+4% +$42.8K 0.01% 741
2025
Q4
$712K Buy
79,200
+14,350
+22% +$198K 0.01% 828
2025
Q3
$1.12M Buy
64,850
+1,816
+3% +$22.4K 0.01% 648
2025
Q2
$591K Buy
63,034
+1,126
+2% +$9.25K 0.01% 799
2025
Q1
$440K Sell
61,908
-2,157
-3% -$21.8K 0.01% 826
2024
Q4
$747K Buy
64,065
+6,396
+11% +$100K 0.01% 706
2024
Q3
$1.18M Buy
57,669
+57,253
+13,763% +$1.32M 0.02% 551
2024
Q2
$9K Sell
416
-146
-26% -$3.48K ﹤0.01% 624
2024
Q1
$15K Buy
562
+35
+7% +$972 ﹤0.01% 605
2023
Q4
$16K Sell
527
-317
-38% -$9.11K ﹤0.01% 555
2023
Q3
$27K Buy
844
+78
+10% +$3.03K 0.01% 517
2023
Q2
$31K Buy
766
+18
+2% +$730 0.01% 507
2023
Q1
$28K Buy
748
+38
+5% +$1.49K 0.01% 512
2022
Q4
$25K Buy
710
+141
+25% +$6.7K 0.01% 482
2022
Q3
$32K Sell
569
-44
-7% -$2.73K 0.01% 454
2022
Q2
$32K Buy
613
+6
+1% +$305 0.01% 471
2022
Q1
$44K Sell
607
-81
-12% -$6.86K 0.01% 467
2021
Q4
$81K Buy
688
+36
+6% +$4.51K 0.03% 372
2021
Q3
$87K Sell
652
-198
-23% -$30K 0.05% 246
2021
Q2
$138K Sell
850
-443
-34% -$34.5K 0.09% 188
2021
Q1
$104K Sell
1,293
-8
-0.6% -$537 0.08% 198
2020
Q4
$71K Sell
1,301
-593
-31% -$21.5K 0.06% 216
2020
Q3
$38K Buy
1,894
+77
+4% +$1.61K 0.03% 242
2020
Q2
$38K Hold
1,817
– – 0.03% 223
2020
Q1
$22K Sell
1,817
-61
-3% -$822 0.02% 234
2019
Q4
$28K Buy
1,878
+223
+13% +$3.1K 0.06% 150
2019
Q3
$22K Sell
1,655
-36
-2% -$574 0.05% 162
2019
Q2
$28K Buy
1,691
+640
+61% +$10.1K 0.07% 145
2019
Q1
$18K Buy
+1,051
New +$15.7K 0.09% 169

Other funds holding NTLA

Benjamin Edwards's NTLA Position: Q3 2026 in Review

Benjamin Edwards increased its Intellia Therapeutics (NTLA) stake by 7.7% in Q3 2026, buying an estimated $77.6K and bringing the position to 87,085 shares worth $1.05M. The position accounts for 0.01% of the portfolio, ranked #792.

Benjamin Edwards first reported a position in NTLA in Q1 2019 and has held it in 31 quarters since. The position peaked at $1.37M in Q2 2026. 239 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Benjamin Edwards held 87,085 shares of Intellia Therapeutics worth $1.05M as of Q3 2026.
  • Benjamin Edwards bought 6,204 Intellia Therapeutics shares in Q3 2026, an estimated $77.6K.
  • Intellia Therapeutics made up 0.01% of Benjamin Edwards's portfolio in Q3 2026, its #792 holding.
  • Benjamin Edwards first reported a position in Intellia Therapeutics in Q1 2019 and has held it in 31 quarters since.
  • Benjamin Edwards's Intellia Therapeutics position peaked at $1.37M in Q2 2026.
  • 239 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Benjamin Edwards's 13F filing for Q3 2026, filed 12 Nov 2026.